Try GOLD - Free
Analysts expect Indian drug companies to strike deals with US to avoid tariff blow
Business Standard
|October 04, 2025
IfSun Pharma is able to strike a Pfizer-like deal, it may avoid US tariff in near term, say experts
Indian players may followin US pharma giant Pfizer’s footsteps and sign deals with the Donald Trumpadministration agreeingtocut drug prices, which, inturn, may providesome relief from tariffs in an uncertain environment where import of patented drugs would attract 100 per cent tariff, analysts said.
Nuvama analysts said that such a move might result ina “temporary removal of overhang on branded pharma” in the US. It is relevant for Sun Pharmaceutical Industries which has exposure to the US innovative drugs market. Ilumya, its largest drug, generates revenue from Medicare Part B (nearly 50-60 percent), while the Medicaid contribution is likely to be around § per cent, according to Nuvama estimates.
This story is from the October 04, 2025 edition of Business Standard.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Business Standard
Business Standard
India needs to find vocations least impacted by AI: CEA Nageswaran
India needs to find vocations that will be least impacted by artificial intelligence (AI) and make it ‘fashionable’ for students to adopt them, in a bid to combat the disruptive impact of Al on job creation, said Chief Economic Advisor V Anantha Nageswaran on Tuesday.
1 mins
November 05, 2025
Business Standard
AEL plans ₹25K cr rights issue over 2 yrs after FPO pullback
Group Chairman Gautam Adani said the recent strategic milestones reflect the group’s long-term commitment to building national infrastructure and next-generation energy and digital platforms.
1 min
November 05, 2025
Business Standard
'Need to drive double-digit top line, and margins in excess of that'
Tata Consumer expects to close the year with margins at 15 per cent. In an interview, Sunil D'Souza, the managing director and chief executive officer of Tata Consumer Products, talks about what led the company to deliver a strong top line in the second quarter despite GST disruptions with Sharleen D'Souza. Edited excerpts:
2 mins
November 05, 2025
Business Standard
Setting sail again
Reviving India’s shipbuilding ambitions
2 mins
November 05, 2025
Business Standard
Pension norms: Last working day could change the maths
The central government has issued a clarification on how pensions and family pensions will be calculated for employees.
1 min
November 05, 2025
Business Standard
Trump’s agenda faces big test in NYC polls
Mamdani will face off against Andrew Cuomo, who is running as an independent, and the Republican nominee Curtis Sliwa
2 mins
November 05, 2025
Business Standard
Lower tea prices to boost Tata Consumer's margins
Brokerages positive on stock amid hopes of spurt in food biz
3 mins
November 05, 2025
Business Standard
US looks to invest in rare-earth firms amid race against China
The Commerce Department and Pentagon on Monday pledged financing and potential equity stakes in a domestic producer of rare-earth magnets that are at the center of a trade war with China, the world’s dominant supplier.
1 min
November 05, 2025
Business Standard
At least 7 dead as trains collide in Chhattisgarh
At least seven people were killed and several injured after a collision between a passenger local train and a goods train in Bilaspur district of Chhattisgarh on Tuesday.
1 mins
November 05, 2025
Business Standard
G2 or not G2? Why 2025 isn’t 1945
Today’s G2 is fundamentally unstable and lacks the power to truly influence the whole world
5 mins
November 05, 2025
Listen
Translate
Change font size